Latest News for: barda

Edit

ProteoNic 2G UNic® Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies

Pharmiweb 15 Dec 2025
ProteoNic 2G UNic® Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies ... and Development Authority (BARDA).
Edit

ProteoNic 2G UNic® Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing ...

Nasdaq Globe Newswire 11 Dec 2025
ProteoNic licenses its 2G UNic technology to Ginkgo Bioworks for a BARDA-backed consortium to boost fast, cost‑effective mAb production against filoviruses ... .
Edit

Designing a rescue medication for adulterated opioids: OX390 program and BARDA partnership (Orexo AB)

Public Technologies 05 Dec 2025
With BARDA (valued up to USD 51 m) for development through FDA approval ... How is BARDA's collaboration accelerating Orexo's development of rescue therapies? ... Orexo News Release OX390 And BARDA Partnership Interview With Ed Kim MD CMO Dec 5 2025.
Edit

Owning your face in the AI age: Why Denmark's new proposed bill matters - opinion

The Jerusalem Post 26 Nov 2025
Denmark has decided to draw a hard line, with a proposed bill establishing identity as property ....
Edit

Rafa Laboratories Awarded up to $186 Million by BARDA to Develop a Life-Saving Intramuscular TXA Injection for Prehospital Care

PR Newswire 19 Nov 2025
This pivotal collaboration, which represents Rafa's second major contract with BARDA, addresses an urgent global need ... BARDA and Rafa are Collaborating on a Comprehensive Development Approach.
Edit

Tivic Secures Barda Meeting for Entolimod(TM) for Acute Radiation Syndrome

Hastings Tribune 18 Nov 2025
Meeting with Radiological and Nuclear Medical Countermeasures Program ... .
Edit

TIVIC SECURES BARDA MEETING FOR ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME (Form 8-K) (Tivic Health Systems Inc)

Public Technologies 18 Nov 2025
TIVIC SECURES BARDA MEETING ... The process enables BARDA to evaluate technology readiness, understand manufacturing and approval requirements, and identify potential pathways to funding and purchasing ... More About BARDA.
Edit

Start2 Group, Inc. Announces BARDA Award to Launch $100M Antiviral Prize Competition

PR Newswire 03 Nov 2025
$100M prize competition announced by BARDA and Start2 Group to develop innovative broad-spectrum antiviral therapies Post this. "We are honored to partner with BARDA to lead this prize competition that ...
Edit

Ginkgo Bioworks Awarded Project Agreement through BARDA's BioMaP-Consortium

PR Newswire 03 Nov 2025
"We are honored to work with BARDA and our BioMaP-Consortium partners to bring these and other innovations to the domestic production of mAb-based medical countermeasures ... This BARDA-supported ...
Edit

Appili Therapeutics to Attend BARDA Innovation Symposium 2025

Nasdaq Globe Newswire 22 Oct 2025
Highlights Government-Funded Pipeline and Expanding Role of Public-Private Partnerships in Biodefense Innovation. Highlights Government-Funded Pipeline and Expanding Role of Public-Private Partnerships in Biodefense Innovation ... .
Edit

True Diagnostics Awarded BARDA RRPV Project to Advance Rapid Biothreat Test

Nasdaq Globe Newswire 20 Oct 2025
The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR), U.S.
Edit

Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its ...

Nasdaq Globe Newswire 02 Oct 2025
CDTX), a biotechnology company using its proprietary Cloudbreak��platform to develop drug-Fc ...
Edit

Orexo US Awarded USD 8 Million by BARDA for OX390 Development Partnership

Pharmiweb 30 Sep 2025
in funding by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response in the US Department of Health and Human Services.
×